Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Work
Year: 2015
Type: article
Source: The Lancet Oncology
Institutions University of California, Los Angeles, Vanderbilt University, Vanderbilt-Ingram Cancer Center, University of Zurich, Essen University Hospital +29 more
Cites: 32
Cited by: 1,497
Related to: 10
FWCI: 106
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze